CRISPR Therapeutics (CRSP)

• Market cap: $5.12B
• 1 day: 0.66%
• 5 days: 2.29%
• 1 month: -0.6%
• 3 months: 36.29%
• 6 months: 29.36%
• Year to date: 35.8%
• 1 year: 22.6%
• 5 years: -33.59%
• 10 years: 299.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Employees: 393

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

74% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 58

61% more capital invested

Capital invested by funds: $2.19B [Q1] → $3.52B (+$1.33B) [Q2]

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

24% more repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 100

10% more funds holding

Funds holding: 387 [Q1] → 424 (+37) [Q2]

8.95% more ownership

Funds ownership: 74.81% [Q1] → 83.77% (+8.95%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $42
• Avg. target: $73
• High target: $105

9 analyst ratings

• positive: 6 67%
• neutral: 3 33%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor	$80	Buy Maintained	7 Aug 2025
Barclays Gena Wang	$56	Equal-Weight Maintained	6 Aug 2025
Chardan Capital Geulah Livshits	$82	Buy Maintained	5 Aug 2025
RBC Capital Luca Issi	$42	Sector Perform Maintained	5 Aug 2025
B of A Securities Geoff Meacham	$78	Buy Maintained	22 Jul 2025